News | January 26, 2024
Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
This turn valve is considered revolutionary because it supports back-to-back drug infusion through the same device
India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
GMM Pfaudler US completes acquisition of MixPro
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Subscribe To Our Newsletter & Stay Updated
